Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455923 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL30539270 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL7079252 | 0.88 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL6237621 | 0.88 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL16288581 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL16288582 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL6446074 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL6446073 | 0.87 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL1341495 | 0.86 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL12071191 | 0.86 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280717-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016164814-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100222546-A1 | METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-02 | — | — | US | disclosed |
| US-20100222546-A1 | METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-02 | — | — | US | disclosed |
| US-20100222549-A1 | DECHALCOGENATIVE METHODS FOR THE PREPARATION OF ALLYLIC SULFIDES | NIH-DEITR | 2010-09-02 | — | — | US | disclosed |
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2009-06-11 | — | — | US | disclosed |
| US-20090118271-A1 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1925309-A1 | NOVEL ANTICANCER CONCOMITANT DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | KRAS, TOP1, ERBB3 | CYP1A2 3036/4885CYP2C9 3689/4885CYP2C19 3880/4885 |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | ADH1A, ADH1C, SLC43A1 | CYP1A2 118/4885CYP2C9 135/4885CYP2C19 158/4885 |
| US-20100222549-A1 | DECHALCOGENATIVE METHODS FOR THE PREPARATION OF ALLYLIC SULFIDES | TST, SCLY, AP2S1 | CYP1A2 634/4885CYP2C9 1081/4885CYP2C19 1077/4885 |
| US-20100222546-A1 | METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES | PTMS, STT3A, GCG | CYP1A2 4285/4885CYP2C9 3685/4885CYP2C19 3944/4885 |
| US-20090118271-A1 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug | TP53, SLC10A1, BRCA1 | CYP1A2 1840/4885CYP2C9 2083/4885CYP2C19 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.